CLVS.Q Stock Overview
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Clovis Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.015 |
| 52 Week High | US$2.87 |
| 52 Week Low | US$0.01 |
| Beta | 0.66 |
| 11 Month Change | -40.00% |
| 3 Month Change | -28.57% |
| 1 Year Change | -99.39% |
| 33 Year Change | -99.77% |
| 5 Year Change | -99.97% |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10
Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05Shareholder Returns
| CLVS.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.1% | 4.0% | 2.0% |
| 1Y | -99.4% | 18.0% | 32.4% |
Return vs Industry: CLVS.Q underperformed the US Biotechs industry which returned 2.5% over the past year.
Return vs Market: CLVS.Q underperformed the US Market which returned 12.6% over the past year.
Price Volatility
| CLVS.Q volatility | |
|---|---|
| CLVS.Q Average Weekly Movement | 61.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CLVS.Q's share price has been volatile over the past 3 months.
Volatility Over Time: CLVS.Q's weekly volatility has increased from 39% to 61% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 413 | Patrick Mahaffy | www.clovisoncology.com |
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Clovis Oncology, Inc. Fundamentals Summary
| CLVS.Q fundamental statistics | |
|---|---|
| Market cap | US$2.18m |
| Earnings (TTM) | -US$251.91m |
| Revenue (TTM) | US$133.02m |
0.0x
P/S Ratio0.0x
P/E RatioIs CLVS.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLVS.Q income statement (TTM) | |
|---|---|
| Revenue | US$133.02m |
| Cost of Revenue | US$31.59m |
| Gross Profit | US$101.43m |
| Other Expenses | US$353.33m |
| Earnings | -US$251.91m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 76.25% |
| Net Profit Margin | -189.37% |
| Debt/Equity Ratio | -158.0% |
How did CLVS.Q perform over the long term?
See historical performance and comparison